Orthobiologics company Royal Biologics has commercially launched a new platelet-rich plasma system, Bioincyte.
Bioincyte converts traditional platelet-rich plasma to platelet-rich fibrin matrix, eliminating extensive contamination of red and white blood cells. Bioincyte converts the PRP through a controlled process that protects and preserves platelets.
It creates a long-lasting environment for platelets to release growth factors. PRFM has several advantages over traditional PRP, including an ability to retain more growth factors, less trauma caused to individual blood cells and controlled time-release abilities.
The Bioincyte system allows patients to be treated in a variety of settings in a matter of minutes, according to a Feb. 14 press release.